NHS Data Access Explorer

Unofficial. This site is an experimental reformatting of data published by NHS England. It is not endorsed by NHS England. Always check the official Data Uses Register before relying on anything here.

Permission to Contact

Agreements naming it
16
In term in September 2026
0
Organisations
11
Files released
0

Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.

How the register describes it

Recorded against the dataset on each agreement, and not always the same from one agreement to the next, so every value found is listed.

Type of data
  • Identifiable
Sensitivity
  • Non-Sensitive
  • Sensitive
Frequency of release
  • One-Off
Legal basis for provision
  • Health and Social Care Act 2012 - s261(5)(c)
  • Health and Social Care Act 2012 – s261(2)(c)

Organisations whose agreements name it (11)

Show the list, with the number of agreements for each

With expired agreements only (11)

Agreements covering this dataset

Showing all 16 agreements.

Files: files of this dataset released under the agreement, across all its versions.

AgreementOrganisationTypeFilesLatest termStatusCommercial
PERMISSION TO CONTACT - VRR - NextCOVE Study: A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 as a booster dose compared with mRNA-1273.222 in participants aged 12 years+ to prevent CV-19 DARS-NIC-705821-P6J0H Modernatx, Inc Research 0 24 May 2023 to 23 May 2024 Expired Yes
A phase I study to determine safety and immunogenicity of the candidate COVID-19 vaccine AZD1222 delivered by aerosol in healthy adult volunteers (COVAXAER01) DARS-NIC-637092-P9K6S Imperial College London Academic 0 20 April 2023 to 19 April 2024 Expired Yes
Phase I Vaccine Study of pEVAC-PS DARS-NIC-594129-R0M3W University Hospital Southampton NHS Foundation Trust NHS Trust 0 16 January 2023 to 15 January 2024 Expired Yes
Study Title: A randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2 Short Title: Evaluating COVID-19 Vaccine Boosters (Covboost) DARS-NIC-456088-R0H0V University Hospital Southampton NHS Foundation Trust NHS Trust 0 8 July 2022 to 7 July 2023 Expired Yes
A Phase 2/3, Randomized, Stratified, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1273.529 (B.1.1.529, Omicron variant) in Comparison with mRNA-1273 (prototype) Booster Vaccine DARS-NIC-623799-T2J4F Modernatx, Inc Research 0 17 February 2022 to 16 February 2023 Expired Yes
Study of Recombinant Protein Vaccines with Adjuvant as a Primary Series and as a Booster Dose against COVID-19 in Adults 18 Years of Age and Older DARS-NIC-526363-C3M1K Sanofi Pasteur Commercial 0 20 July 2021 to 19 July 2022 Expired Yes
A Phase II, randomised, single-blind, platform trial to assess safety, reactogenicity and immunogenicity of COVID-19 vaccines in pregnant women in the United Kingdom (Preg-CoV) DARS-NIC-526384-M3T5R St. George’s Hospital Medical School Academic 0 20 July 2021 to 19 July 2022 Expired No
Phase II/III Study of AZD2816, a Vaccine for the Prevention of COVID-19 in Adults DARS-NIC-474218-V7G7L AstraZeneca UK Limited Commercial 0 23 June 2021 to 22 June 2022 Expired Yes
A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older DARS-NIC-436453-C4N4Z Medicago R&D Incorporated Research 0 23 March 2021 to 22 March 2022 Expired Yes
Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2) DARS-NIC-448303-Z7H5R University of Oxford Academic 0 23 March 2021 to 22 March 2022 Expired No
Comparing COVID-19 Vaccine Schedule Combinations (Com-COV) DARS-NIC-428459-V7Q8M University of Oxford Academic 0 29 January 2021 to 28 January 2022 Expired No
A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS. DARS-NIC-418208-J1Y6J Valneva Austria GmbH Commercial 0 23 March 2021 to 30 November 2021 Expired Yes
PROVENT - A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19 DARS-NIC-409290-L1F3L AstraZeneca UK Limited Commercial 0 22 October 2020 to 31 March 2021 Expired Yes
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older DARS-NIC-409280-J6T3M Janssen-Cilag Limited Supplier 0 16 November 2020 to 31 March 2021 Expired Yes
Novavax DARS-NIC-401171-F9Z8T National Institute for Health Research Research 0 26 October 2020 to 31 January 2021 Expired Yes
Investigating a vaccine against COVID-19 DARS-NIC-396423-H4Z6Z University of Oxford Academic 0 16 October 2020 to 31 December 2020 Expired Yes

Cite this page

NHS England (2026) Data Uses Register, September 2026 edition, agreements naming Permission to Contact. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/datasets/permission-to-contact/ (accessed [date]).

This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.